Real-World Study Reveals Early Success of Upadacitinib in AD

TOPLINE: Upadacitinib was well tolerated in patients with moderate to severe atopic dermatitis (AD) and led to disease control as early as 1 month, with sustained improvements up to 12 months. METHODOLOGY: Researchers conducted the UP-TAINED study to assess the effectiveness and safety of upadacitinib for over 2 years…